UHCDS a-tDCS + TE in Fibromyalgia Patients

Fibromyalgia Clinical Trial

Official title:

Efficacy of Unihemispheric Concurrent Dual-Site Anodal Transcranial Direct Current Stimulation Combined With Therapeutic Exercise on Pain in Fibromyalgia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06169748
• Other study ID #: UHCDS a-tDCS+ TE FM Pain
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 8, 2024
• Est. completion date: July 9, 2024

Study information

• Verified date: December 2023
• Source: University of Castilla-La Mancha
• Contact: Rubén Arroyo Fernández, PhD
• Phone: +34678915760
• Email: Ruben.Arroyo[@]uclm.es
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study aims to investigate the effect of a Unihemispheric Concurrent Dual-Site anodal Transcranial Direct Current Stimulation combined with therapeutic exercise on pain in subjects with FM.

Description:

Fibromyalgia (FM) syndrome is characterized as a cardinal symptom of chronic pain. It is one of the rheumatic diseases with the greatest impact on quality of life.

Although the etiology and pathophysiology are not yet completely clear, FM is related to specific changes in brain activity, such as a decrease in blood flow in the thalamus, caudate nucleus and pons tegmentum. This could be related to the appearance of a disorder in pain regulation, characterized by an alteration of the sensory and pain process in the central nervous system, due to neuroplastic changes in the neural circuits related to pain. Imaging studies have shown that FM could be associated with functional changes in the brain, such as a reduction in connectivity in efferent pain inhibitory pathways and central sensitization in afferent pain pathways, resulting in an increase in pain perception.

The most common FM treatment guidelines recommend aerobic exercise as the only non-pharmacological therapy with level A recommendation in the treatment of FM. In the same way, it concludes that it is more than recommended to combine therapies assuming synergistic effects between them.

Neuromodulation treatments with transcranial direct current stimulation (tDCS) have been shown to induce significant analgesia in FM through the modification of sensory processing of pain by thalamic inhibitory circuits. To date, the few studies that have combined tDCS and therapeutic exercise in FM have applied tDCS to the primary motor cortex (M1) in isolation. Currently, several studies conclude that Unihemispheric Concurrent Dual-Site anodal Transcranial Direct Current Stimulation (UHCDS a-tDCS) on the dorsolateral prefrontal cortex (DLPFC) and M1 produces a 50% greater modulation of corticospinal excitability in healthy subjects. To date, there is no study that has evaluated the effectiveness of this novel application of tDCS in subjects with FM on pain.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 105
• Est. completion date: July 9, 2024
• Est. primary completion date: June 11, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 65 years.

• Fulfilled the 2010 American Colleague of Rheumatology criteria for fibromyalgia.

• Usual pain intensity of 4 or more points on a visual analogue scale.

• Able to participated in a therapeutic exercise program.

• Understanding of spoken and written Spanish.

Exclusion Criteria:

• Pregnancy or breastfeeding.

• Metallic implants in the head.

• Tumor, trauma or surgery in the brain.

• Epilepsy or stroke.

• History of substance abuse in the last 6 months.

• Use of carbamazepine in the last 6 months.

• Diagnosed psychiatric pathology.

• Rheumatic pathology not medically controlled.

• Coexisting autoimmune pathology.

• Chronic inflammatory disease (rheumatoid arthritis, erythematosus systemic lupus, inflammatory bowel disease).

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Device:
• Real UHCDS a-tDCS
Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
• Sham UHCDS a-tDCS
Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
• Therapeutic exercise
The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.

Locations

Country	Name	City	State
Spain	Hospital General Nuestra Señora del Prado	Talavera De La Reina	Toledo

Sponsors (1)

Lead Sponsor	Collaborator
University of Castilla-La Mancha

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain intensity.	It will be measured with a visual analog scale (VAS) of 100 millimeters in length. The subject has to indicate the level of pain he feels, being 0 the absence of pain and 100 the maximum imaginable.	Baseline; inmediately after intervention; 3-months after intervention.
Primary	Referred pain area after suprathreshold pressure stimulation.	A pressure algometer (Force Ten™, Wagner Instruments, USA) will be used. It will be performed on the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) at a constant suprathreshold pressure (20% above the pressure pain threshold) for 60 seconds.	Baseline; inmediately after intervention; 3-months after intervention.
Secondary	Anxiety.	The version adapted to Spanish from the State Scale (STAI-ES) of the State-Trait Anxiety Inventory (STAI) will be used. STAI-ES ranges from 0 to 60 points, with higher values indicating higher levels of anxiety.	Baseline; inmediately after intervention; 3-months after intervention.
Secondary	Pain catastrophizing.	The Spanish version of the Pain Catastrophizing Scale (PCS) will be used. PCS ranges from 0 to 52 points, with higher values indicating higher levels of catastrophizing.	Baseline; inmediately after intervention; 3-months after intervention.
Secondary	Depression.	The adaptation to the Spanish of Beck Depression Inventory II (BDI-II) will be used. BDI-II ranges from 0 to 63 points, with higher values indicating higher levels of depression.	Baseline; inmediately after intervention; 3-months after intervention.